Leukemia - Table of Contents alert Volume 30 Issue 7

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 30, Issue 7 (July 2016) In this issue Commentary Original Articles Letters to the Editor Correspondence Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement We are pleased to announce that the Impact Factor* for Leukemia is now 12.104 - an increase from 10.431 last year. LEU is ranked 8 of 213 titles in the oncology category and 1 of 70 in the hematology category. The journal would like to thank all our authors, reviewers and readers for their continued support. (*Thomson Reuters, 2015 Journal Citation Reports®) Submit your research Commentary Top How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? G Barosi and R P Gale Leukemia 2016 30: 1453-1455; advance online publication, April 29, 2016; 10.1038/leu.2016.75 Full Text Original Articles Top ACUTE MYELOID LEUKEMIA Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia Y Zhou, M Othus, D Araki, B L Wood, J P Radich, A B Halpern, M Mielcarek, E H Estey, F R Appelbaum and R B Walter Leukemia 2016 30: 1456-1464; advance online publication, February 29, 2016; 10.1038/leu.2016.46 Abstract | Full Text LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia X Wang, Q Lin, F Lv, N Liu, Y Xu, M Liu, Y Chen and Z Yi Leukemia 2016 30: 1465-1474; advance online publication, March 8, 2016; 10.1038/leu.2016.50 Abstract | Full Text Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo A Sergeeva, H He, K Ruisaard, L St John, G Alatrash, K Clise-Dwyer, D Li, R Patenia, R Hong, P Sukhumalchandra, M J You, M Gagea, Q Ma and J J Molldrem Leukemia 2016 30: 1475-1484; advance online publication, March 8, 2016; 10.1038/leu.2016.57 Abstract | Full Text Genetic alterations and their clinical implications in older patients with acute myeloid leukemia C-H Tsai, H-A Hou, J-L Tang, C-Y Liu, C-C Lin, W-C Chou, M-H Tseng, Y-C Chiang, Y-Y Kuo, M-C Liu, C-W Liu, L-I Lin, W Tsay, M Yao, C-C Li, S-Y Huang, B-S Ko, S-C Hsu, C-Y Chen, C-T Lin, S-J Wu and H-F Tien Leukemia 2016 30: 1485-1492; advance online publication, March 17, 2016; 10.1038/leu.2016.65 Abstract | Full Text CHRONIC MYELOGENOUS LEUKEMIA A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia OPEN M Wagle, A M Eiring, M Wongchenko, S Lu, Y Guan, Y Wang, M Lackner, L Amler, G Hampton, M W Deininger, T O'Hare and Y Yan Leukemia 2016 30: 1493-1501; advance online publication, March 8, 2016; 10.1038/leu.2016.51 Abstract | Full Text The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia W Huang, C-H Luan, E E Hjort, L Bei, R Mishra, K M Sakamoto, L C Platanias and E A Eklund Leukemia 2016 30: 1502-1509; advance online publication, March 17, 2016; 10.1038/leu.2016.66 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells K Hayakawa, A M Formica, M J Colombo, S A Shinton, J Brill-Dashoff, H C Morse III, Y-S Li and R R Hardy Leukemia 2016 30: 1510-1519; advance online publication, March 8, 2016; 10.1038/leu.2016.61 Abstract | Full Text LYMPHOMA Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance S Spinner, G Crispatzu, J-H Yi, E Munkhbaatar, P Mayer, U Höckendorf, N Müller, Z Li, T Schader, H Bendz, S Hartmann, M Yabal, K Pechloff, M Heikenwalder, G L Kelly, A Strasser, C Peschel, M-L Hansmann, J Ruland, U Keller, S Newrzela, M Herling and P J Jost Leukemia 2016 30: 1520-1530; advance online publication, March 8, 2016; 10.1038/leu.2016.49 Abstract | Full Text MOLECULAR TARGETS FOR THERAPY BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells Z Xu, P P Sharp, Y Yao, D Segal, C H Ang, S L Khaw, B J Aubrey, J Gong, G L Kelly, M J Herold, A Strasser, A W Roberts, W S Alexander, C J Burns, D C S Huang and S P Glaser Leukemia 2016 30: 1531-1541; advance online publication, March 8, 2016; 10.1038/leu.2016.52 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis G Kong, Y-I Chang, A Damnernsawad, X You, J Du, E A Ranheim, W Lee, M-J Ryu, Y Zhou, Y Xing, Q Chang, C E Burd and J Zhang Leukemia 2016 30: 1542-1551; advance online publication, February 29, 2016; 10.1038/leu.2016.40 Abstract | Full Text MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation Y Huang, J A I Thoms, M L Tursky, K Knezevic, D Beck, V Chandrakanthan, S Suryani, J Olivier, A Boulton, E N Glaros, S R Thomas, R B Lock, K L MacKenzie, J H Bushweller, J W H Wong and J E Pimanda Leukemia 2016 30: 1552-1561; advance online publication, March 8, 2016; 10.1038/leu.2016.55 Abstract | Full Text EPIDEMIOLOGY Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia N Gunnarsson, M Höglund, L Stenke, S Wållberg-Jonsson, F Sandin, M Björkholm, A Dreimane, M Lambe, B Markevärn, U Olsson-Strömberg, H Wadenvik, J Richter and A Själander Leukemia 2016 30: 1562-1567; advance online publication, March 8, 2016; 10.1038/leu.2016.59 Abstract | Full Text ANIMAL MODELS Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma K Shimada, S Shimada, K Sugimoto, M Nakatochi, M Suguro, A Hirakawa, T D Hocking, I Takeuchi, T Tokunaga, Y Takagi, A Sakamoto, T Aoki, T Naoe, S Nakamura, F Hayakawa, M Seto, A Tomita and H Kiyoi Leukemia 2016 30: 1568-1579; advance online publication, March 22, 2016; 10.1038/leu.2016.67 Abstract | Full Text Letters to the Editor Top Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) E Schuler, A Giagounidis, D Haase, K Shirneshan, G Büsche, U Platzbecker, F Nolte, K Götze, R F Schlenk, A Ganser, A Letsch, F Braulke, M Lübbert, G Bug, P Schafhausen, U Bacher, N Gattermann, M Wulfert, R Haas and U Germing Leukemia 2016 30: 1580-1582; advance online publication, December 15, 2015; 10.1038/leu.2015.340 Full Text In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche H Zong, S Sen, G Zhang, C Mu, Z F Albayati, D G Gorenstein, X Liu, M Ferrari, P A Crooks, G J Roboz, H Shen and M L Guzman Leukemia 2016 30: 1582-1586; advance online publication, December 16, 2015; 10.1038/leu.2015.343 Full Text Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) B Bhatnagar, J S Blachly, J Kohlschmidt, A-K Eisfeld, S Volinia, D Nicolet, A J Carroll, A W Block, J E Kolitz, R M Stone, K Mrózek, J C Byrd and C D Bloomfield Leukemia 2016 30: 1586-1589; advance online publication, December 16, 2015; 10.1038/leu.2015.345 Full Text Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway M M Pan, Q Y Zhang, Y Y Wang, P Liu, R B Ren, J Y Huang, L T Chen, X D Xi, Z Chen and S J Chen Leukemia 2016 30: 1590-1593; advance online publication, December 17, 2015; 10.1038/leu.2015.347 Full Text Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials OPEN P D le Coutre, T P Hughes, F-X Mahon, D-W Kim, J L Steegmann, N P Shah, K Gooden, N Wallis and J E Cortes Leukemia 2016 30: 1593-1596; advance online publication, December 21, 2015; 10.1038/leu.2015.352 Full Text SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6 J Palomero, M C Vegliante, A Eguileor, M L Rodríguez, P Balsas, D Martínez, E Campo and V Amador Leukemia 2016 30: 1596-1599; advance online publication, December 29, 2015; 10.1038/leu.2015.355 Full Text Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia R Marke, J Havinga, J Cloos, M Demkes, G Poelmans, L Yuniati, D van Ingen Schenau, E Sonneveld, E Waanders, R Pieters, R P Kuiper, P M Hoogerbrugge, G J L Kaspers, F N van Leeuwen and B Scheijen Leukemia 2016 30: 1599-1603; advance online publication, December 29, 2015; 10.1038/leu.2015.359 Full Text Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development C Bueno, E H J van Roon, A Muñoz-López, A Sanjuan-Pla, M Juan, A Navarro, R W Stam and P Menendez Leukemia 2016 30: 1603-1606; advance online publication, December 29, 2015; 10.1038/leu.2015.362 Full Text Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy Z Chen, J E Cortes, J L Jorgensen, W Wang, C C Yin, M J You, E Jabbour, H M Kantarjian, L J Medeiros and S Hu Leukemia 2016 30: 1606-1609; advance online publication, February 3, 2016; 10.1038/leu.2016.6 Full Text Deregulation of HOX genes by DNMT3A and MLL mutations converges on BMI1 Y-T Tan, Y Sun, S-H Zhu, L Ye, C-J Zhao, W-L Zhao, Z Chen, S-J Chen and H Liu Leukemia 2016 30: 1609-1612; advance online publication, February 8, 2016; 10.1038/leu.2016.15 Full Text An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells A Jakobs, S Uttarkar, C Schomburg, S Steinmann, A Coulibaly, P Schlenke, W E Berdel, C Müller-Tidow, T J Schmidt and K-H Klempnauer Leukemia 2016 30: 1612-1615; advance online publication, February 8, 2016; 10.1038/leu.2016.16 Full Text Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients S Soverini, C De Benedittis, C Papayannidis, K Machova Polakova, C Venturi, D Russo, P Bresciani, A Iurlo, M Mancini, A Vitale, S Chiaretti, R Foà, E Abruzzese, F Sorà, A Kohlmann, T Haferlach, M Baccarani, M Cavo and G Martinelli Leukemia 2016 30: 1615-1619; advance online publication, February 12, 2016; 10.1038/leu.2016.17 Full Text The possible perils of targeted therapy U Duffner, A Abdel-Mageed, J Younge, C Tornga, K Scott, J Staddon, K Elliott, J Stumph and P Kidd Leukemia 2016 30: 1619-1621; advance online publication, February 9, 2016; 10.1038/leu.2016.18 Full Text Identification of MYC mutations in acute myeloid leukemias with NUP98–NSD1 translocations V-P Lavallée, S Lemieux, G Boucher, P Gendron, I Boivin, S Girard, J Hébert and G Sauvageau Leukemia 2016 30: 1621-1624; advance online publication, February 9, 2016; 10.1038/leu.2016.19 Full Text The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers M Meggendorfer, C Haferlach, M Zenger, K Macijewski, W Kern and T Haferlach Leukemia 2016 30: 1624-1627; advance online publication, February 9, 2016; 10.1038/leu.2016.21 Full Text Correspondence Top Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach S S Young, T Tucker, I Bosdet and A Karsan Leukemia 2016 30: 1628-1629; advance online publication, March 8, 2016; 10.1038/leu.2016.37 Full Text Reporting results for deep molecular responses in chronic myeloid leukemia A A Morley Leukemia 2016 30: 1630-1631; advance online publication, May 17, 2016; 10.1038/leu.2016.94 Full Text Deep molecular response in chronic myeloid leukemia N C P Cross and A Hochhaus Leukemia 2016 30: 1632; advance online publication, May 13, 2016; 10.1038/leu.2016.78 Full Text Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.